Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3661-3680 of 3,900 trials

Narcolepsy and Idiopathic Hypersomnia: ALKS 2680 Study

We are investigating the safety and tolerability of ALKS 2680 for people with narcolepsy and idiopathic hypersomnia. The study also looks at its effects on excessive daytime sleepiness and cataplexy.

Narcolepsy and Idiopathic Hypersomnia>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Multiple Myeloma: Comparing Treatment Approaches

We are studying two treatment plans for newly diagnosed multiple myeloma patients who cannot have a transplant. Our goal is to see which plan helps more patients reach a state of minimal disease.

Multiple MyelomaConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Cholesterol Management: Fixed Dose Combination Study

We are evaluating a new combination pill of bempedoic acid, ezetimibe, and atorvastatin for patients managing high cholesterol. The goal is to see if this combination works as well as taking each medication separately.

Healthy Participants≤3 monthsSafety phase (I)CardiologyInternal Medicine

Cystic Fibrosis: Nebulized Bacteriophage Treatment

We are studying a new nebulized treatment for adults with cystic fibrosis and chronic Pseudomonas lung infection. The goal is to see if it helps reduce the infection and improve lung function and quality of life.

Cystic Fibrosis≤3 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

ALS Treatment: EH-301 and N-Acetylcysteine with Riluzole

We are studying a new combination therapy for people with ALS to see if it can slow disease progression and improve muscle strength and quality of life. This trial compares the treatment to a placebo to evaluate its effectiveness.

Amyotrophic Lateral Sclerosis (ALS)1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Chronic Heart Failure: Vitamin D and Oral Iron Study

We are studying whether vitamin D combined with oral iron can improve symptoms in patients with chronic heart failure and iron deficiency. This trial compares it to standard intravenous iron treatment to see which is more effective.

Chronic Heart FailureIron Deficiency3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Non-Small Cell Lung Cancer: QL2107 vs. Keytruda®

We are comparing a new treatment, QL2107, to Keytruda® for patients with resected non-small cell lung cancer. The study aims to see if QL2107 works similarly in the body and to evaluate its safety and immune response.

Non-small Cell Lung Cancer1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

PM14 Treatment for Soft Tissue Sarcomas and Solid Tumors

We are studying how PM14 works alone and with radiotherapy in patients with soft tissue sarcomas and other solid tumors. The goal is to find the best treatment approach and understand its safety and effectiveness.

Soft Tissue Sarcomas and Other Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncologyOrthopedics and Traumatology

THN391 for Early Alzheimer's Disease

We are testing a new medication to see if it is safe and well-tolerated in people with early Alzheimer's disease. This study will help us understand how the drug works in the body.

Alzheimer's Disease1-2 yearsSafety phase (I)Neurology

Nucresiran for Transthyretin Amyloidosis with Cardiomyopathy

We are studying whether Nucresiran can help reduce serious heart-related events in patients with transthyretin amyloidosis. The trial compares its effects to a placebo to assess overall health improvements.

Transthyretin Amyloidosis with Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Plaque Psoriasis: Oral Piclidenoson Study

We are testing an oral medication called piclidenoson for people with moderate-to-severe plaque psoriasis. The goal is to see if it can significantly improve skin symptoms compared to a placebo.

Plaque Psoriasis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Momelotinib for Anemia in Low-Risk Myelodysplastic Syndrome

We are studying whether momelotinib can improve red blood cell counts in patients with low-risk myelodysplastic syndrome. The trial also looks at the safety of this treatment.

Myelodysplastic Syndrome3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Metastatic Colorectal Cancer: Fruquintinib and Tislelizumab Study

We are studying a new treatment combining Fruquintinib and Tislelizumab for patients with metastatic colorectal cancer without active liver metastases. The goal is to evaluate its effectiveness and safety while also assessing quality of life.

Metastatic Colorectal Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Cerebrospinal Fluid Disorders: MRI Contrast Agent Study

We are testing a new MRI contrast agent to assess cerebrospinal fluid flow in adults with CSF disorders. This may help improve diagnosis and treatment of central nervous system conditions.

Idiopathic Intracranial HypertensionIntracranial CystsPrimary or Secondary Brain Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyOtolaryngology

Type 1 Diabetes: Once-Weekly Insulin Icodec vs. Daily Insulin Glargine

We are studying whether a new once-weekly insulin can help adults with type 1 diabetes manage their blood sugar levels as well as the standard daily insulin. This trial will also look at safety and patient experiences.

Type 1 Diabetes6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesDiabetologyEndocrinology

Botox for Hidradenitis Suppurativa Treatment

We are studying whether Botox can help reduce symptoms in patients with Hidradenitis Suppurativa. This trial will assess changes in skin condition and patient satisfaction over several months.

Hidradenitis SuppurativaMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesAllergologyDermatology

High-Risk Essential Thrombocythaemia: STP938 Treatment Study

We are evaluating a new medication for adults with high-risk essential thrombocythaemia who have not tolerated or responded to standard treatment. The study aims to assess its safety and early effects.

Essential Thrombocythaemia>2 yearsSafety phase (I)Hematology

CART84 Treatment for Relapsed Acute Leukemias

We are studying a new infusion treatment called CART84 for patients with relapsed or refractory acute myeloid leukemia and acute lymphoblastic T leukemia. The goal is to evaluate its safety and effectiveness in helping patients achieve remission.

Relapsed/Refractory Acute Lymphoblastic T Leukemia (T-ALL)Relapsed/Refractory Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Infective Endocarditis: Oral vs. Parenteral Antibiotics

We are comparing oral antibiotics to outpatient parenteral antibiotics for treating infective endocarditis. The goal is to see if oral treatment is as effective and to assess patient satisfaction and costs.

Infective Endocarditis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInfectious Diseases

Kidney Transplant: Autologous Tolerogenic Dendritic Cells

We are testing a new treatment using patients' own immune cells to help highly sensitized kidney transplant recipients accept their new organ. This study aims to improve transplant success rates for these individuals.

Kidney Transplant>2 yearsSafety phase (I)NephrologyUrology